Recent studies have shown that inhibiting the neonatal crystallizable fragment receptor (FcRn), a receptor for the crystallizable fragment (Fc) of immunoglobulin G (IgG), can effectively reduce the level of IgGs and alleviate the severity of humoral autoimmune disorders such as myasthenia gravis [13], experimental ulcerative colitis [14], chronic inflammatory demyelinating neuropathy [15] and primary immune thrombocytopenia [16]. Here, FCGRT is linked to myasthenia gravis.